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Malaria is a major public health problem in Ethiopia. Plasmodium falciparum and Plasmodium vivax co-exist and
malaria rapid diagnostic test (RDTs) is vital in rendering parasite-confirmed treatment especially in areas where
microscopy from 2008 to 2010 is not available. CareStartTM Malaria Pf/Pv combo test was evaluated compared to
microscopy in Butajira area, south-central Ethiopia. This RDT detects histidine-rich protein-2 (HRP2) found in P.
falciparum, and Plasmodium enzyme lactate dehydrogenase (pLDH) for diagnosis of P. vivax. The standard for the
reporting of diagnostic accuracy studies was complied. Among 2,394 participants enrolled, 10.9% (n=87) were
Plasmodium infected (household survey) and 24.5% (n=392) health facility-based using microscopy. In the
household surveys, the highest positivity was caused by P. vivax (83.9%, n=73), P. falciparum (15.0%, n=13), and the
rest due to mixed infections of both (1.1%, n=1). In health facility, P. vivax caused 78.6% (n=308), P. falciparum
caused 20.4% (n=80), and the rest caused by mixed infections 1.0% (n=4). RDT missed 9.1% (n=8) in household and
4.3% (n=17) in health facility-based surveys among Plasmodium positive confirmed by microscopy while 3.3%
(n=24) in household and 17.2% (n=208) in health facility-based surveys were detected false positive. RDT showed
agreement with microscopy in detecting 79 positives in household surveys (n=796) and 375 positives in health
centre survey (n=1,598).
RDT performance varied in both survey settings, lowest PPV (64.3%) for Plasmodium and P. falciparum (77.2%) in
health centres; and Plasmodium (76.7%) and P. falciparum (87.5%) in household surveys. NPV was low in P. vivax in
health centres (77.2%) and household (87.5%) surveys. Seasonally varying RDT precision of as low as 14.3% PPV
(Dec. 2009), and 38.5% NPV (Nov. 2008) in health centre surveys; and 40-63.6% PPV was observed in household
surveys. But the influence of age and parasite density on RDT performance was not ascertained. Establishing quality
control of malaria RDT in the health system in areas with low endemic and where P. falciparum and P. vivax co-exist
is recommendable. CareStartTM RDT might be employed for epidemiological studies that require interpreting the
results cautiously. Future RDT field evaluation against microscopy should be PCR corrected.
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In Ethiopia, approximately 68% of the recently estimated
92 million total population, about 63 million people, is
at risk of malaria infection [1,2]. Typically malaria is sea-
sonal and unstable [3], and consequently epidemics of
different magnitude were common in the past [3-5].
Even though the occurrence of all human malaria para-
sites is reported, Plasmodium falciparum and Plasmo-
dium vivax are epidemiologically the most important
malaria parasites in the country [4]. Plasmodium falcip-
arum has been the major causes of high case fatality.
Since 2005, the National Malaria Control Programme in-
tensified the deployment of key malaria interventions in-
cluding artemisinin-combination therapy (ACT), malaria
rapid diagnostic tests (RDTs), and vector control mea-
sures [6]. Thus, in recent years, malaria burden de-
creased [7,8], and large-scale epidemics were absent [9].
Malaria RDTs were introduced as one of the diagnostic
methods following the revision of malaria diagnosis and
treatment guideline in 2004 [10]. The principle of a RDT
is to capture malaria antigen from peripheral blood flowing
across a membrane containing specific anti-malaria anti-
bodies. Thus, there are different types of RDTs depending
on the antigen they target: those targeted to histidine-rich
protein-2 (HRP-2) only detect P. falciparum, those
which target the parasite enzyme lactate dehydrogenase
(LDH) and aldolase that can detect non- falciparum
from mixed infection. LDH test uses either monoclonal
antibodies which react with LDH of all species including
P. falciparum (or known as Pan-LDH), or antibodies
specific for P. falciparum LDH [11-13]. RDTs can also
detect P.vivax-specific LDH.
RDTs for detection of only P. falciparum were
recommended [10], and have been used at health posts
in Ethiopia since 2005 [14,15]. However, RDTs that de-
tect HRP-2 have got some practical limitations and
guide treatment [13,16]. Following the intensive malaria
interventions since 2005, the dominance of P. vivax was
documented in some highland areas [17,18]. At commu-
nity level malaria diagnosis and treatment using RDTs
target P. falciparum, and consequently P. vivax may be
misdiagnosed as malaria negative and treated based on
clinical grounds. Moreover, World Health Organization
(WHO) recommends that malaria case management be
based on parasite-based diagnosis [19]. Thus, the intro-
duction of RDTs targeted to detect both P. falciparum
and P. vivax is helpful in improving the early diagnosis
and treatment of malaria at peripheral areas. CareStart™
Malaria Pf/Pv combo test was among multi-species
detecting RDT according to WHO product testing [20].
Various field evaluations of CareStart™ Malaria Pf/Pv
combo test were underway since 2007 in different
parts of Ethiopia [21-25]. However, in general, malaria
diagnostics have performed differently across eco-epidemiological settings, leading to varying estimates of
agreement between tests [26-28].
There is paucity of information regarding the precision
of malaria RDTs in the low-endemic highland zones of
Ethiopia. Therefore, the present study was aimed at
evaluating the performance of CareStart™ at health cen-
tres and concurrent surveys in highland areas of south-
central Ethiopia.
Methods
Study area and population
This study was conducted in Butajira area, situated
130 km south of Addis Ababa, in six of ten kebeles
(the smallest administrative unit) part of the Demo-
graphic Surveillance site (DSS) of Butajira Rural Health
Programme (BRHP) [29], and administratively located in
Meskan District, Gurage Zone, Ethiopia. Butajira Town
is the base of the BRHP-DSS, which is located along
Addis Ababa-Hosaena highway and 50 km West of
Ziway Town, adjacent to Ziway Lake in the Rift Valley.
The study area is situated in intermediate highland zone
with elevation of between 1,800 and 2,300 meters above
sea level (masl). Moreover, the study area was part of the
Ethiopian Malaria Prediction System project [30]. The
detailed description of the study area was presented in
another recent study [31].
There were 58,335 people living in the BRHP-DSS in
2008 and half (50.1%, n = 29,243) of the population were
female. Of those 26,834 (46%) people lived in the study
area. Malaria is endemic in the area with frequent
outbreak that caused significant cases and deaths as
documented previously [32]. The local population get
in-patient services at Butajira Zonal Hospital (a public-
owned), which is located in Butajira Town, and Mercy
Hospital (a non-governmental organization situated
about 10 km outside the town). In addition, out-patient
services are obtained from Butajira, Enseno, and Hamus
Gebeya health centres as well as at private clinics. More-
over, each study kebele has a health post. Drug venders
are also available in Butajira Town.
This study was conducted while the National Malaria
Control Program of Ethiopia has initiated various local
academic and research institutions for field evaluation of
RDTs that could detect multi-species and replace RDTs
that only detect P. falciparum. Thus, CareStartTM Mal-
aria Pf/Pv combo test was among the options for the
field evaluation before introducing to malaria control
program of the country.
Survey design and sampling
A prospective household and health facility-based sur-
veys were conducted to assess the performance of
CareStart™ Malaria Pf/Pv combo test in reportedly fe-
brile cases between 2008 and 2010. Six rural kebeles
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Yeteker and Wurib were randomly selected. A total of
750 households were selected randomly from those
kebeles, using probability proportion to size (PPS) sam-
pling. Individuals with the history of fever in the previ-
ous 48 hours of the survey period were included in both
household and health facility-based surveys. Febrile
cases visiting outpatient department (OPD) suspected of
malaria cases at Butajira and Enseno health centres were
recruited. In general, this study complied with Standards
for Reporting of Diagnostic Accuracy guidelines (STARD)
to improve the quality of reporting [33].
Six cross-sectional surveys were performed on the
same households for two consecutive years. The surveys
were conducted in October-November 2008 (a month
after the main rainy season), January-February 2009 (dry
season), June-July 2009 (main rainy season), October-
November 2009, January-February 2010, and June 2010
in the household surveys. The health facility-based sur-
vey was done during October 2008, November 2008,
August 2009, September 2009, October 2009, November
2009, and December 2009 (Figure 1). The health facility-
based survey was done at Butajira Health Centre (≥ 2,
000 masl) and Enseno Health Centre (< 2,000 masl). In-
dividuals with a history of fever in the previous 48 hours
were enrolled. But severely-ill people were excluded.
Data collection
Data collection was done using pre-tested structured
questionnaire and format prepared for this purpose. Pre-
testing of the data collection tool was performed in
an adjacent kebele but outside the study area. Intensive
training of data collectors and supervisors was
conducted. All data collectors were supplied with a
training manual and field guide. Data collectors and su-
pervisors for both the household and health facility-Figure 1 Number of participants varying among survey
seasons, Butajira area, Ethiopia, 2008-2010.BRHP-DSS enumerators and supervisors did household
interview in the baseline household survey, and guided
and facilitated the data collection in the follow up of
household surveys. A coordinator of the Butajira base fa-
cilitated recruitment of data collectors and supervised
the data collection with the principal investigator (AW).
The health facility-based survey was organized as a re-
search team of four health personnel assigned from the
same health centre. Overall, the study was supervised by
the principal investigator (AW), a laboratory technician,
and two OPD staffs were the member of the team. A
health centre head was responsible for coordination of
the survey. Those OPD staffs each assigned to screen
malaria suspected febrile cases at pediatric and adult
OPD separately. During the data collection, participants
were requested for blood specimen to be screened for
malaria parasite using CareStart™ Malaria Pf/Pv combo
test (Access Bio, Inc., New Jersey, USA; LOT H28: V,
Expiry July 2010). In addition, thin and thick film was
prepared immediately for microscopic examination.
CareStart™ RDTs are individually packaged with alcohol
swab, lancet, capillary tube, buffer, and test device.
Both blood slides and the RDT devices were given
identical code for later comparison of results. Specimen
collection and reporting result for the malaria RDT was
performed using the recommended procedures by the
company [34]. First, 5 μl of blood specimen was added
into sample well of the test device using a capillary sup-
plied with the kit for this purpose. Second, two drops of
assay buffer was added into the buffer well. The results
of CareStart™ were declared within 20 minutes, while
thin and thick films were kept for later examination
using microscopy. The RDT result was recorded along a
registry book using the participant code.
Then, thin and thick films were prepared and Giemsa-
stained for comparison using light microscopy. Blood
specimen processing, examination, and reporting of re-
sults were performed using standard guidelines [35]. In
brief, the smears were air dried, placed in slide boxes,
and examined by a trained microscopist at the field la-
boratory in Butajira. Thin films were fixed with metha-
nol, and both thin and thick films were stained with 3%
Giemsa stain for 30 min. Microscopic examination was
done at 1,000× magnification. During the microscopic
examination, a slide was regarded as negative after 100
fields had been examined without finding any parasites.
When slides were Plasmodium positive, asexual parasite
count was performed using standard procedures of
light microscopy as recommended by World Health
Organization [35]. The number of asexual parasites per
200 white blood cells (WBCs), or 500 WBCs for low
density infections, were used to compute the number of
asexual parasites per μl of blood, assuming a standard
count of 8,000 WBCs per μl of blood [35].
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of the test
CareStart™ Malaria Pf/Pv combo test contains a mem-
brane strip, which is pre-coated with two monoclonal
antibodies as two separate lines across a test strip. One
monoclonal antibody (test line 2) is specific to pLDH of
P. vivax. Other lines (test line 1) is printed with a mono-
clonal antibody specific to HRP2 of P. falciparum, and
the control area (line 3). So, the CareStart™ Malaria Pf/
Pv combo test is designed for the differential diagnosis
between P. vivax and P. falciparum [34]. The following
five options including the presence of: i) two bands (one
band in the control area and another band in the “1”
area) indicates a positive result for P. falciparum; ii) two
colour bands (one band in the control area and another
band in the “2” area) indicates a positive result for P.
vivax; iii) three colour bands (bands in the control area,
“1” area and “2” area) indicates a positive result for
mixed infection for P. falciparum and P. vivax; iv) only
one band in the control area within the result window
indicates a negative result; and v) the test is invalid if the
line in the control area does not appear were used in the
interpretation of RDT results [34]. In addition, the inten-
sity of bands was carefully recorded for the test positives
using guidelines for interpretation of RDT results avail-
able from the manufacturing company.
Comparison with light microscopy and quality control
A malaria microscopist temporarily stationed at BRHP-
DSS [29], did the microscopic examination using stand-
ard procedure [35]. In the household surveys, a single
slide was prepared from each individual. Thin and thick
blood films from were dried and daily transported to the
temporary laboratory for staining and parasite investiga-
tion. Similarly, the slides from health centres were
processed and investigated for malaria parasite at the
same laboratory. The malaria microscopist was blinded
to malaria RDT results. Similarly, health professionals
were blinded to microscopy results. Febrile cases re-
quested for blood film to be checked for malaria using
CareStart™. Study participants were sent to laboratory
and duplicate slides with thin and thick films were pro-
duced simultaneously. One of the slides was used for the
routine microscopic examination and results dispatched
accordingly. Another slide was processed and regularly
sent to the temporary laboratory at BRHP-DSS.
In order to assure quality of the microscopic examina-
tions, in both surveys, the entire positive and 10% of the
negative slides were sent to senior malaria microscopist
and re-examined at Adama Malaria Control Laboratory,
Adama Town, Ethiopia. In the household surveys, seven
of 2,094 slides (0.3%) showed discordant results. A third
reader, blinded to the previous results, re-examined the
seven discrepant slides (six vivax malaria and onenegative). Similar procedure was followed for the survey
held at health centres. Each reader was blinded to the
RDT results and others’ slide reading results. To ensure
maximum participation, households with absentees were
re-visited once.
Ethical consideration
This study obtained ethical approval from Institutional
Review Board of the College of Health Sciences of the
Addis Ababa University, and from the Ministry of Sci-
ence and Technology of Ethiopia. Local health author-
ities at all levels also gave permission to conduct the
study. Individual informed consent was obtained from
adults, and from the parents or guardians of children
aged less than 18 years. In addition, minors gave verbal
assent. All study participants including minors had the
right to refuse. Blood specimens were collected aseptic-
ally using an alcohol swab and disposable blood lancets
by trained staff. All people found to be malaria positive
during the survey were treated directly according to the
national guideline [10].
Febrile patients were screened for malaria parasites on
the spot using the RDT, and blood slides were also col-
lected for the survey to investigate the nature of the mal-
aria parasite using light microscopy. Malaria positive
cases detected using malaria RDTs were treated immedi-
ately. Moreover, those found to be malaria positive on
microscopy were also treated. Plasmodium vivax posi-
tives were treated with chloroquine, 25 mg/kg for three
days (10 mg base per kg on days 1 and 2, and 5 mg base
per kg on day 3). Artemether-lumefantrine (20 mg
artemether plus 120 mg lumefantrine in a fixed dose
combination) was administered, based on body weight,
two times a day for three days to Plasmodium falcip-
arum-positive patients [10]. In addition, CoartemW and
chloroquine stocks were kept at health facilities in the
study area for treatment of cases that occurred between
surveys.
Data management and analysis
Data entry and cleaning was done using Epi Info version
6 (Centres for Disease Control and Prevention, Atlanta,
Georgia, USA) and exported to SPSS. Data analysis was
performed using IBM SPSS Statistics 20. Sensitivity, spe-
cificity, positive and negative predictive values of the test
was computed with 95% confidence interval (CI) by tak-
ing malaria microscopy as reference.
The kappa statistic or agreement between the test and
microscopy was calculated using data observed and
probability of expected as recommended [36]. A kappa
value of 1 indicates perfect agreement, whereas a kappa
of 0 indicates agreement equivalent to chance. The other
kappa values of 0.81-0.99 (almost perfect), 0.61-0.80
(substantial), 0.41-0.60 (moderate), 0.21-0.40 (fair), 0.01-
Total febrile cases malaria suspected with 
complete data (N=2,394)
Health centres (n=1,598)Household survey 
(n=796)
Microscopy (n=796) Microscopy (n=1,598)
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used for interpretation [36]. The evaluation of the per-
formance of the test was based on requirement that
RDTs must achieve, which is expected to be ≥ 95% sensi-
tivity and >90% specificity to be useful diagnostic [37].
The results from January-February 2010 and June 2010
surveys was excluded from analysis of age and seasonal
variation of RDT performance because of finding null
and a single malaria positive, respectively.Negative 
(n=709)
Negative 
(n= 1,206)
Positive (n=87)
PF=13, PV=73 
F+V=1
Positive (n=392)
PF= 80, PV= 308 
F+V=4
CareStart RDT (n=796) CareStart RDT (1.598)
Negative 
(n=693) Negative (n=1,015)
Positive 
(n=103)
PF=21, PV=78, 
F+V=4
Positive (n=583)
PF=176, PV=397 
F+V=10
Figure 2 Flow chart of microscopy and CareStartTM Malaria
RDT results, Butajira area, Ethiopia, 2008-2010.Results
Characteristics of study participants
The evaluation of CareStartTM performance was based
on self-reported 2,394 febrile cases from public health
facilities (66.8%, n = 1,598) and household surveys
(33.2%, n = 796). The participants’ mean (±SD) age was
13.9 ± 13.0 (from one month to 70 years), and median
10 years in health centre surveys, and 19.7 ± 18.2 (from
one month to 99 years) with median 13 years in house-
hold surveys. More participants were recruited from
Enseno Health Centre (73.7%, 1,178 of 1,598) than from
Butajira Health Centre (26.3%, 420 of 1,598) in health
facility-based surveys. A total of 31 infants (six from
household and 25 from health centre surveys) were
suspected for malaria screened (Data not shown).
Seasonal variation of malaria suspected cases ob-
served in both survey settings, which was higher dur-
ing October-November 2008 in household surveys,
and October 2009 and November 2009 at health cen-
tres (Figure 1).Microscopy results
The microscopic results showed that 10.9% (n = 87) of
people examined were Plasmodium positive in the
household surveys. Of those, 83.9% (n = 73) were caused
by P. vivax, 15.0% (n = 13) were due to P. falciparum,
and the rest 1.1% (n = 1) were mixed infections due
to both vivax and falciparum malaria. Similarly, 24.5%
(n = 392) of people were malaria infected among febrile
cases visited health centres. Among them, 78.6% (n = 308)
were P. vivax, 20.4% (n = 80) were P. falciparum, and
the rest 1.0% (n = 4) were mixed infections due to both
vivax and falciparum malaria (Figure 2). Eight of 25
(32%) children below six months were diagnosed as
P. vivax infected.
Microscopy and RDT showed agreement for 79 posi-
tives in household and 375 positives in health centre sur-
vey results. RDT missed 9.1% (n = 8) in household and
4.3% (n = 17) in health facility-based surveys among
Plasmodium positive confirmed by microscopy. Simi-
larly, 3.3% (n = 24) in household and 17.2% (n = 208) in
health facility-based surveys were detected false positive.
No invalid test results were observed (Figure 2).Plasmodium infection varied among different age
groups, and males were more infected than females in
both survey settings. Higher proportion of the malaria
infection occurred during peak malaria transmission in
both survey settings. About 67% of the total positives
cases were screened during October-November 2009
and about 20% during October-November 2008 in
household surveys. Moreover, above half of the positives
during October 2009 and one-fifths during August and
November 2009 each, in the health facility-based surveys
(Table 1).
RDT compared to microscopy
Table 2 presents the sensitivity, specificity, positive and
negative predictive values of CareStartTM RDT compared
to microscopy in both surveys. CareStartTM RDT showed
low sensitivity in overall Plasmodium (90.8%) and P. fal-
ciparum (87.5%) in household survey; and in P. vivax
(92.8%) in health facility surveys. Similarly, low specifi-
city observed in overall Plasmodium (82.7%), and
P. falciparum (92.8%) in health facility surveys, and in
P. vivax (87.5%) in household surveys.
Moreover, lowest PPV was determined in overall Plas-
modium (64.3%) and P. falciparum (77.2%) in health fa-
cility; and overall Plasmodium (76.7%) and P. falciparum
(87.5%) in household surveys. Negative predictive value
of the test was good in both overall Plasmodium and P.
falciparum. However, lowest NPV was found in P. vivax
in both health facility (77.2%) and household (87.5%)
surveys. The test and microscopy showed almost perfect
Table 1 Characteristics of study participants in household and health facility-based surveys, Butajira area, Ethiopia,
2008-2010
Factors Household survey
(N = 796), n%
Microscopy positive
(n = 87), n(%)
Health centres
(N = 1,598), n (%)
Microscopy positive
(n = 392), n(%)
Age groups
<5 178 (22.4) 27 (31.0) 495 (31.0) 117 (29.8)
5-9 150 (18.8) 28 (32.2) 293 (18.0) 84 (21.4)
10-14 86 (10.8) 10 (11.5) 179 (11.2) 56 (14.3)
≥15 382 (48.0) 22 (25.3) 63 (39.5) 135 (34.4)
Gender
Male 382 (48.0) 48 (55.2) 754 (47.2) 203 (51.8)
Female 414 (52.0) 39 (44.8) 844 (52.8) 189 (48.2)
Seasons
Oct.-Nov.2008 603 (75.7) 17 (19.5)
Oct. 2008 63 (3.9) 9 (2.3)
Nov.2008 18 (1.1) 12 (3.1)
Jan.-Feb.2009 46 (5.8) 2 (2.3)
Jun.-Jul. 2009 46 (5.8) 9 (10.3)
Aug. 2009 156 (9.8) 76 (19.4)
Sept. 2009 28 (1.8) 13 (3.3)
Oct.-Nov.2009 100 (12.6) 58 (66.7)
Oct.2009 721 (45.1) 201 (51.3)
Nov.2009 521 (32.6) 78 (19.9)
Dec.2009 91 (5.7) 3 (0.8)
Jan.-Feb.2010 0
Jun.2010 1 (0.1) 1 (1.0)
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(Table 2).
Factors affecting RDT performance
The relationship of RDT precision and survey seasons,
age and parasite density in all survey settings is
presented in Figures 3, 4, 5 and 6 below. Figure 3 pre-
sents varying RDT performance among different seasonsTable 2 Performance of CareStartTM Malaria Pf/Pv combo test
area, Ethiopia, Oct.2008-Jun. 2010
Setting/indicators Sensitivity Specificity
Health Centres
All Plasmodium 95.7 (93.2-97.3) 82.7 (80.5-84.8)
P. falciparum* 95.9 (88.7-98.6) 92.8 (89.3-95.2)
P. vivax* 92.8 (89.3-95.2) 95.9 (88.7-98.6)
Household surveys
All Plasmodium 90.8 (82.9-95.3) 96.6 (95.0-97.7)
P. falciparum* 87.5 (52.9-97.8) 98.5 (91.9-99.7)
P. vivax* 98.5 (91.9-99.7) 87.5 (52.9-97.8)
*Mixed infections excluded, PPV = Positive predictive value, NPV = Negative predictiin household surveys. Sensitivity varied between 82.3%
and 100%, and specificity between 78.4% and 98.6%.
Low sensitivity (82.3) was observed during October-
November 2008 and low specificity (78.4%) during June-
July 2009. The lowest PPV of 63.6% (October-November
2008), 40.0% (January-February 2009), and 50.0% (June-
July 2009) was obtained; and it appears corresponding
with malaria infection of 19.5%, 2.3% and 10.3%,in household and health facility-based surveys, Butajira
PPV NPV Kappa
64.3 (60.3-68.1) 98.3 (97.3-99.0) 0.69
77.2 (67.6-84.5) 98.9 (96.8-99.6) 0.81
98.9 (96.8-99.6) 77.2 (67.6-84.5) 0.81
76.7 (67.7-83.8) 98.8 (97.7-99.4) 0.81
87.5 (52.9-97.8) 98.5 (91.9-99.7) 0.86
98.5 (91.9-99.7) 87.5 (52.9-97.8) 0.86
ve value.
Figure 3 Sensitivity, specificity, predictive value positive and
negative of CareStartTM Malaria RDT in different seasons in the
household surveys, Butajira area, Ethiopia, Oct.2008-Nov. 2009.
Figure 5 Sensitivity, specificity, predictive value positive and
negative of CareStartTM Malaria RDT in different age groups in
household surveys, Butajira area, Ethiopia, Oct.2008-Nov. 2010.
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better during October-November 2009 (Figure 3). Al-
though a recent study reported overall low malaria
prevalence (0.9%), higher malaria prevalence during
October-November 2009 [31]. In health facility surveys,
the sensitivity was between 93.6% and 100%. Good sensi-
tivity of from 98.7% to 100% were observed, except the
relatively low sensitivity during October 2009 (94.5%)
and November 2009 (93.6%). Specificity was (73.6-
96.3%) while substantial differences exist in PPV and
NPV. Low PPV of 60.9-92.3% in all seasons, and the
least (14.3%) in December 2009. Highest NPV (97.3-
100%) was obtained, except the lowest (38.5%) was found
in November 2008, which overlapped with a few malaria
suspected cases (n = 18) were screened (Figure 4).
Precision of RDT in different age groups using house-
hold surveys is presented in Figure 5. Low sensitivity
was seen in <5 aged (84.6%) and 5-9 aged (89.5%)Figure 4 Sensitivity, specificity, predictive value positive and
negative of CareStartTM Malaria RDT in different seasons in
health facility surveys, Butajira area, Ethiopia,
Oct.2008-Dec. 2009.children compared to older children, 10-14 years (100%)
and ≥15 years (95.4%). However, good specificity with al-
most similar precision (94.7-97.5%) was revealed in dif-
ferent age categories; and low PPV (67.7-89.3%), and
highest NPV (97.3-100%) was determined. In health
facility-based surveys, RDT demonstrated persistently
good sensitivity (95.2-100%) in children aged between <5
and 10-14 years, except 93.3% in ≥15 years. Low specifi-
city (72.4%-84.9%) and PPV (59.7-71.4) was observed in
all age groups, extremely low PPV in <5 and ≥15 years
(Figure 6). NPV was the highest throughout the survey
in both survey settings.
In health facilities, 4.5% (n = 10) of microscopy con-
firmed P. vivax, and 5.9% (n = 5) of P. falciparum with
asexual parasite count of ≥ 500 p/μl were not detected
by CareStart™ RDT. Moreover, the RDT failed detecting
10.3% (n = 7) of vivax malaria, five of those with ≥ 500 p/μlFigure 6 Sensitivity, specificity, predictive value positive and
negative of CareStartTM Malaria RDT in different age groups in
health facility surveys, Butajira area, Ethiopia,
Oct.2008-Dec. 2009.
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http://www.malariajournal.com/content/12/1/218and the rest two with <200 p/μl in household survey. Only
a single (1 of 13) falciparum case was missed by RDT in
household survey (Table 3). Sixteen of 87 (18.4%) positives
were reportedly sick of malaria and half of those took anti-
malarial treatment. Most of the cases were due to P. vivax
(n = 15) (data not shown).
Discussion
This study found varying precision of CareStart™ RDT
to detect P. falciparum and P. vivax in “active” and clin-
ical settings of highland-fringe areas of south-central
Ethiopia. A greater proportion of RDTs than slides gave
positive result for Plasmodium. In the survey, the test
showed low sensitivity and high specificity for P. falcip-
arum, but vice versa for P. vivax. The test revealed lower
PPV for P. falciparum and lower NPV for P. vivax.
Overall, season substantially influences RDT precision
with good sensitivity at health facilities compared to
household survey. However, specificity was found to be
low in both settings with comparable results. Interest-
ingly, better NPV obtained unlike lowest PPV in both
survey settings. RDT showed low sensitivity in children
aged below 10 years. No strong evidence for contribu-
tion of low parasite density for missed Plasmodium de-
tection by the test product.
This study has got some limitations. This study used
light microscopy for comparison of performance of
RDT, in spite of its shortcomings related to variable
techniques in specimen preparation and slide reading,
and mainly the level of expertise of the examining mi-
croscopist [11]. Thus, PCR could be the ideal gold
standard in RDT evaluation [11], as applied in recent
studies [38,39]. The use of PCR appears plausible in
hypoendemic areas like the present study area [40].Table 3 Comparison of asexual parasite count per micro-liter
surveys, Butajira area, Ethiopia, 2008-2010
Setting/Plasmodium Plasmodium vivax (n = 220)
Health centres visit RDT negative, n RDT po
60-199 0 0
200-499 0 5
500-4,999 3 107
5,000-90,000 7 98
Total, n (%) 10 (4.5) 210 (95
Setting/Plasmodium Plasmodium vivax (n = 68)
Household surveys RDT negative, n RDT po
40-199 2 3
200-499 0 4
500-4,999 4 36
5,000-90,000 1 18
Total, n (%) 7 (10.3) 61 (89.7There might be a possibility of multiple enrollments of
participants between the two survey settings. Some of
the strengths of this study include generating large sam-
ple data in different seasons at highlands of low malaria
endemicity unlike other studies recent studies. RDT
evaluation was performed using well trained and compe-
tent health personnel at different settings. It is believed
that the strengths of this study outweigh the limitations.
Thus, conclusions drawn and recommendations sug-
gested are considerably valuable both in improving mal-
aria control efforts and future research endeavor.
The present finding of low sensitivity for P. falciparum
(87.5%) and P. vivax (92.8%) using CareStart™ RDT is
comparable with a study conducted in south-west
(85.6% for P. falciparum, and 85.0% for P. vivax) and
North-West (92.9% for P. falciparum, 90.9% for P. vivax)
Ethiopian highland areas [21,24]. But the present finding
reported lower sensitivity compared to other studies in
South (99.4% for P. falciparum and P. vivax); North-East
(98.5% P. falciparum and 98.0% for P. vivax); and South-
West (96.4% for P. falciparum, and 95.3% for P. vivax)
Ethiopia [22,23,25]. The low PPV value obtained in this
study is in line with a study in South-West Ethiopia [21],
and in low endemicity areas elsewhere [27].
The varying RDT performance in different seasons in
the present household survey is generally consistent with
another study in hypoendemic highland zones in Kenya
and Uganda [26]. Moreover, the finding of low PPV and
temporally varying correspondingly with prevalence
using household survey is in agreement with other stud-
ies [26,40]. However, the results with good sensitivity
and specificity from health facility were consistent with
other studies done at health facilities [22,23,25]. The
present finding of the lowest PPV and NPV during two(p/μl) and RDT result in health centres and household
Plasmodium falciparum (n = 85)*
sitive, n RDT negative, n RDT positive, n
0 1
0 5
2 19
3 55
.5) 5 (5.9) 80 (94.1)
Plasmodium falciparum (n = 13)
sitive, n RDT negative, n RDT positive, n
1 0
0 0
0 6
0 6
) 1 (7.7) 12 (92.3)
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http://www.malariajournal.com/content/12/1/218months, November and December 2009, end of malaria
transmission season normally in most parts of Ethiopia.
The present result is in line with a recent study [40].
The finding of less variability in RDT performance in
different age categories is consistent with an evidence
that showed age has no effect on malaria RDT perform-
ance [41].
Various factors such as clinical and epidemiologic
characteristics of the study populations, reference stan-
dards and products of different lots influence the results
of RDT-based diagnosis [11,13,16]. Thus, comparison of
RDT results difficult. Similarly, the present study used
data generated from large population and varying trans-
mission seasons. However, field evaluation of CareStart™
RDT precision used a short duration of peak malaria
transmission.
The present finding of low sensitivity of P. vivax
(health facilities) and P. falciparum (survey) disagrees
with other studies that consistently found multi-species
RDTs to better detect P. falciparum infection than non-
falciparum infection, most probably P. vivax [12,42].
The low sensitivity in health centres for P. vivax may be
interpreted as due to low performance of multi-species
RDTs for this species. The low sensitivity obtained in
this study may be explained by several factors pertinent
to the manufacturing process and environmental condi-
tions [11,16,20]. The present study was performed in
highland area with no extreme weather condition.
In addition, low-prevalence, or hypoendemic, malaria
poses particular diagnostic challenges since low popula-
tion prevalence reduces the PPV of tests [40]. Moreover,
test sensitivity suffers when parasite densities within in-
dividual infections are low [43]. The hypoendemicity di-
minishes test sensitivity, as well as the PPV [43]. Very
low overall prevalence of malaria was found in the
present study area [31], which is known to influence
RDT performance as reported [40].
The varying performance of sensitivity for P. falcip-
arum and P. vivax for survey and health facility might
be interpreted as the difference in clinical condition of
patients. Study participants visiting health facilities
might be clinically more specific than otherwise. Review
evidences showed that higher RDT sensitivity in studies
involving patients seeking relief from moderate to severe
disease in clinical settings while low RDT sensitivity in
studies that enrolled patients by means of “active” case
finding [11,41].
The RDT had low NPV for P. vivax at both survey and
health centres. A past study showed that less sensitive
for non-P. falciparum than for P. falciparum [44]. There
is rich evidence that extremely low sensitivity for both
HRP-2 and p-LDH tests and batch specific problems
were suspected [16]. This implies that RDT missed some
malaria cases or false negatives were higher. Reviewevidence cited a study that occasional false negative re-
sults may be caused by: (i) deletion or mutation of the
HRP-2 gene; (ii) anti-HRP-2 antibodies in humans may
explain why some tests were negative despite significant
parasitemia; and (iii) presence of an inhibitor in the pa-
tient’s blood preventing development of the control line
[13]. The present finding of low PPV in P. falciparum is
likely due to sequestration [45]. False positive RDT re-
sults occur in a few percent of tests, which can be due
to cross-reactivity with rheumatoid factor in blood
[16,20]. Cross-reactivity with heterophile antibodies may
also occur [13].Conclusions
In conclusion, it appears plausible to put malaria RDT
quality control system in place for health systems oper-
ating in highlands with low endemicity and seasonally
varying transmission where P. falciparum and P. vivax
co-exist. CareStart™ RDT could be used for epidemio-
logical studies and results interpreted cautiously by con-
sidering its seasonal variation. Future research targeted
to RDT evaluation should consider the use of a more
sensitive reference standard such as PCR.
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